Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Integrated BioPharma (INBP) reported a quarterly revenue decline of approximately 22.0% for the three months ended September 30, 2026. Revenue was $9.913 million, compared with $12.689 million a year earlier. A gross loss of $112,000 replaced gross profit of $1.019 million, while an operating loss of $961,000 compared with operating income of $163,000.
The net loss was $691,000, versus net income of $123,000. Basic and diluted loss per share were $0.02, compared with earnings of $0.00 per share. Cost of sales fell to $10.025 million from $11.670 million, and selling and administrative expenses fell to $849,000 from $856,000. An income tax benefit of $232,000 compared with a $73,000 expense. The two largest customers in the Contract Manufacturing Segment represented approximately 88% of total revenue, up from 87% a year earlier.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Minor pointCost of sales fell to $10.025 million from $11.670 million in the prior-year quarter.
- Minor pointSelling and administrative expenses declined to $849,000 from $856,000 in the prior-year quarter.
- Minor pointIncome tax benefit of $232,000 compared with a $73,000 expense in the prior-year quarter.
- Minor pointOther income, net rose to $38,000 from $33,000 in the prior-year quarter.
Negative
- Major pointNet loss of $691,000 versus $123,000 profit; basic and diluted EPS fell to $(0.02) from $0.00.
- Moderate pointQuarterly revenue of $9.913 million declined approximately 22.0% from $12.689 million a year earlier.
- Moderate pointGross loss of $112,000 replaced gross profit of $1.019 million in the prior-year quarter.
- Moderate pointOperating loss of $961,000 compared with operating income of $163,000 in the prior-year quarter.
- Minor pointTwo largest Contract Manufacturing customers accounted for approximately 88% of total revenue, versus 87% a year earlier.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HILLSIDE, NJ / ACCESS Newswire / November 13, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2026.
Revenue for the quarters ended September 30, 2026 was
For the quarter ended September 30, 2026, the Company had a net loss of approximately
"Our revenue decreased by approximately
A summary of our financial results for the three months ended September 30, 2026 and 2025 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
Total revenue | $ | 9,913 | $ | 12,689 | ||||
Cost of sales | 10,025 | 11,670 | ||||||
Gross (loss) profit | (112 | ) | 1,019 | |||||
Selling and administrative expenses | 849 | 856 | ||||||
Operating (loss) income | (961 | ) | 163 | |||||
Other income, net | 38 | 33 | ||||||
(Loss) income before income taxes | (923 | ) | 196 | |||||
Income tax (benefit) expense, net | (232 | ) | 73 | |||||
Net (loss) income | $ | (691 | ) | $ | 123 | |||
Basic net (loss) income per common share | $ | (0.02 | ) | $ | 0.00 | |||
Diluted net (loss) income per common share | $ | (0.02 | ) | $ | 0.00 | |||
Weighted average common shares outstanding -basic | 31,059,610 | 31,059,610 | ||||||
Weighted average common shares outstanding -diluted | 31,059,610 | 31,421,338 | ||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact:
Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.